

1 **Rapid detection of SARS-CoV-2 variants of concern identifying a cluster of B.1.1.28/P.1**
2 **variant in British Columbia, Canada**

3 Nancy Matic^{1,2*}, Christopher F. Lowe^{1,2*}, Gordon Ritchie^{1,2}, Aleksandra Stefanovic^{1,2}, Tanya
4 Lawson¹, Willson Jang¹, Matthew Young¹, Winnie Dong³, Zabrina L. Brumme^{3,4}, Chanson J.
5 Brumme^{3,5}, Victor Leung^{1,2,5}, Marc G. Romney^{1,2}

6 ¹ Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada

7 ² Department of Pathology and Laboratory Medicine, University of British Columbia,
8 Vancouver, Canada

9 ³ British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada

10 ⁴ Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

11 ⁵ Department of Medicine, University of British Columbia, Vancouver, British Columbia,
12 Canada

13 * These first authors contributed equally to this article.

14 Word Count: 50

15 Abstract Word Count: 1,197

16

17 **Corresponding Author:**

18 Dr. Marc G. Romney

19 St. Paul's Hospital, Providence Health Care

20 1081 Burrard St.

21 Vancouver, BC, Canada V6Z 1Y6

22 Email: mromney@providencehealth.bc.ca

23 Tel: 604-806-8188

24 **Abstract**

25 Using a real-time RT-PCR-based algorithm to detect SARS-CoV-2 variants of concern, we
26 rapidly identified 77 variants (57-B.1.1.7, 7-B.1.351, and 13-B.1.1.28/P.1). This protocol enabled
27 our laboratory to screen all SARS-CoV-2 positive samples for variants, and identified a cluster
28 of B.1.1.28/P.1 cases, a variant not previously known to circulate in British Columbia.

29

30

31 **Introduction**

32 A robust surveillance system for early identification of SARS-CoV-2 variants of concern
33 (VOC) is of critical public health importance. VOC have demonstrated *in vitro* evasion of
34 antibody neutralization by the K417N/T, E484K, and N501Y substitutions in the spike
35 protein(1–3), and have displayed potential for enhanced transmission due to mutations within the
36 spike receptor binding domain(4,5). Surveillance data from the United Kingdom demonstrated a
37 rapid increase in SARS-CoV-2 cases beginning in September 2020, subsequently attributed to
38 the B.1.1.7 variant(6). This variant has since become the predominant strain in several European
39 countries, and its prevalence is increasing worldwide(7). The B.1.1.7 variant demonstrated
40 dropout of the S gene on a commercial SARS-CoV-2 real-time RT-PCR assay in the UK due to a
41 deletion mutation within the spike protein (69/70), and subsequently proposed as a surveillance
42 strategy by the European Centre for Disease Prevention and Control(8).

43 The B.1.1.28/P.1 variant is an emerging VOC with cases first documented in Japan and
44 Brazil. Within months, it has become the predominant strain in certain regions of Brazil, and has
45 now been detected across several continents, although relatively few cases have been detected in
46 Canada and the United States to date. Re-infection in patients with pre-existing SARS-CoV-2
47 immunity has been described, raising concerns about resurgence(9). Unlike B.1.1.7, the
48 B.1.1.28/P.1 variant does not possess the 69/70 deletion mutation, highlighting the need for a
49 versatile and comprehensive VOC surveillance strategy capable of detecting multiple mutations.

50 Given the potential for VOC to enhance transmission and mortality, and possibly evade
51 natural and/or vaccine-induced immune responses, it is critical to identify VOC cases and
52 monitor their prevalence. Though whole-genome sequencing (WGS) of random subsets of
53 SARS-CoV-2 samples is a core surveillance strategy, this laborious and costly strategy is

54 currently limited by lack of scalability and prolonged turnaround time. We propose a rapid VOC
55 surveillance strategy using multiple real-time RT-PCR assays designed to detect key mutations
56 among all specimens testing positive for SARS-CoV-2 in a clinical diagnostic laboratory.

57 **Methods**

58 From January 25–March 1, 2021, nasopharyngeal swabs and saliva/mouth rinse samples
59 with SARS-CoV-2 detected at any cycle threshold (Ct) value (reported as ‘positive’ or
60 ‘indeterminate’) in our clinical virology laboratory were subsequently tested for VOC. SARS-
61 CoV-2 detection was performed using the LightMix® ModularDx SARS-CoV (COVID19) E-
62 gene assay (TIB Molbiol, Berlin, Germany), with use of the MagNA Pure Compact or MagNA
63 Pure 96 and LightCycler 480, or with the cobas® SARS-CoV-2 Test (Roche Molecular
64 Diagnostics, Laval, QC) on the cobas® 6800. VOC were detected with the VirSNiP SARS-CoV-
65 2 Mutation Assays for Strain Surveillance (TIB Molbiol), targeting specific spike protein
66 variations (N501Y, delHV69/70, K417N, E484K, V1176F). Samples were first screened for
67 N501Y, and if detected, subsequent targets were re-tested to discriminate between the most
68 prevalent VOC within our community (B.1.1.7-delHV69/70 and B.1.351-K417N) and newly
69 emerging VOC (B.1.1.28/P.1-V1176F).

70 WGS was performed on the MinION (Oxford Nanopore Technologies) using the ARTIC
71 nCOV-2019 sequencing protocol V.1 (J. Quick) using V3 primers or Illumina MiSeq with a
72 modified ARTIC nCOV-2019 protocol. Accurate basecalling of MinION was performed using
73 guppy 3.1.5, and FASTQ files analyzed on the bugseq.com platform using pangoleARN.
74 Illumina sequence data were analyzed with the in-house bioinformatics pipeline MiCall(10).

75 This study was approved by the Providence Health Care/University of British Columbia
76 and Simon Fraser University Research Ethics Boards (H20-01055).

77 **Results**

78 During the study period, 31,833 clinical samples were tested for SARS-CoV-2, with
79 2,618 instances of SARS-CoV-2 detected at any Ct value. Of these, 2,430 (92.8%) underwent
80 subsequent testing for the three major VOC categories (B.1.1.7; B.1.351; B.1.1.28/P.1). Note that
81 1.6% (38/2,430) of the samples failed to amplify using the N501Y assay, of which 71% (27/38)
82 were reported as ‘indeterminate’ for SARS-CoV-2, reflecting late Ct values and presumably low
83 viral loads. From the remaining 2,392 samples, 77 VOC were identified (57-B.1.1.7, 7-B.1.351,
84 and 13-B.1.1.28/P.1). Over the course of the study, VOC detection among diagnostic samples
85 rapidly increased (Figure). Notably, identified VOC included a large cluster of the B.1.1.28/P.1
86 variant not previously identified in British Columbia. All B.1.1.28/P.1 variants were initially
87 suspected from the K417N assay, for which PCR products were identified at a lower melting
88 temperature than expected. All the suspected B.1.1.28/P.1 variants were positive when re-
89 screened using the V1176F target. The first presumptive B.1.1.28/P.1 variant identified was
90 confirmed by WGS, detecting the following mutations in the S gene (characteristic of
91 B.1.1.28/P.1): L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y,
92 T1027I, and V1176F. Sequencing also confirmed B.1.1.7 and B.1.351 samples detected by our
93 PCR-based strategy.

94 **Discussion**

95 Timely identification is critical to identify emerging SARS-CoV-2 VOC that may be
96 more transmissible, pathogenic and/or evade both natural and vaccine-induced immunity. The
97 implementation of a PCR-based algorithm to detect VOC has enabled our laboratory to rapidly
98 detect new variants that are in the very early stages of community transmission. Critically, our
99 protocol enabled detection of VOC within 24 hours of COVID-19 diagnosis, a marked advantage

100 over sequencing-based surveillance strategies. Over the study period, VOC positivity rate was
101 3.2%, but detection rates increased markedly over time, as might be expected with exponential
102 growth observed in other countries.

103 Although B.1.1.28/P.1 had not previously been reported in our region, presence of this
104 variant was suspected upon observation of K417N PCR products with a lower melting
105 temperature than wild-type, suggestive of a non-K417N substitution such as the K417T mutation
106 in the B.1.1.28/P.1 variant(11). Follow-up testing of these samples using the V1176F target
107 supported the presumptive identification of B.1.1.28/P.1, which was subsequently confirmed by
108 WGS. By testing all positive SARS-CoV-2 samples for VOC, it enabled the rapid detection of a
109 discrete, new B.1.1.28/P.1 cluster.

110 Although the primary modality of VOC surveillance has been through WGS, universal
111 sequencing of SARS-CoV-2 positive specimens is limited by both laboratory and bioinformatics
112 capacity(12). Due to the volume of VOC testing required, high complexity and cost of WGS and
113 limited laboratory capacity, turnaround time for VOC by WGS may be on the order of days to
114 weeks. With the onset of the COVID-19 pandemic, molecular diagnostics (i.e., PCR) have been
115 increasingly adopted by laboratories to promptly identify SARS-CoV-2 cases, with infrastructure
116 established for this modality of testing. A PCR-based algorithm for the molecular detection of
117 VOC could be rapidly adopted to provide almost real-time resulting of VOC to inform infection
118 prevention and control and public health measures(7,13,14).

119 While the most prevalent VOC worldwide harbour the N501Y spike mutation, it is not
120 present in all variants(15). A PCR-based algorithm for identifying VOC that uses N501Y as the
121 initial screening target, such as in this study, must acknowledge this limitation. Given the rapid
122 emergence of new variants, ongoing surveillance is key, and any laboratory considering a PCR-

123 based algorithm would need to adapt the algorithm as VOC prevalence changes. Nevertheless,
124 the ability to rapidly leverage existing molecular infrastructure established during the COVID-19
125 pandemic to presumptively identify the most prevalent VOC within 24 hours would be an
126 important tool to complement WGS performed at reference laboratories.

127 In summary, our implementation of a real-time RT-PCR-based algorithm enabled
128 identification of the most common VOC to date (B.1.1.7, B.1.351, and B.1.1.28/P.1) within 24
129 hours. This methodology would allow laboratories to perform VOC testing on all positive SARS-
130 CoV-2 samples, and enhance VOC surveillance capacity to identify cases and support decision
131 making for interrupting transmission.

132 **Acknowledgements**

133 We are grateful to our medical laboratory technologists who are highly committed to
134 patient care and laboratory quality improvement. We would also like to acknowledge
135 contributions from John Harding and Althea Hayden [Vancouver Coastal Health (VCH) Public
136 Health], and the BCCDC Public Health Laboratory.

137 This work was supported by COVID-19 rapid response grants from GenomeBC (COV-
138 115 to ZLB, CFL; COV-033 to CJB), an Exceptional Opportunities Fund – COVID-19 award
139 from the Canada Foundation for Innovation (CJB, CFL), a British Columbia Ministry of Health -
140 Providence Health Care Research Institute COVID-19 Research Priorities Grant (CJB, CFL) and
141 Public Health Agency of Canada COVID-19 Immunology Task Force COVID-19 Hot Spots
142 Competition Grant (ZLB, MGR). GR reports participation as a Roche Diagnostics Sequencing
143 Advisory Panel member. ZLB holds a Scholar Award from the Michael Smith Foundation for
144 Health Research.

145



146 **References**

- 147 1. Liu Y, Liu J, Xia H, Xianwen Z, Fontes-Garfias CR, Swanson KA, et al. Neutralizing
148 Activity of BNT162b2-Elicited Serum — Preliminary Report. *N Engl J Med* [Internet].
149 2021 Feb 28. <https://www.nejm.org/doi/full/10.1056/NEJMc2102017>
- 150 2. Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-
151 CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited
152 sera. *Nat Med* [Internet]. 2021 Mar 1. [https://www.nature.com/articles/s41591-021-01270-](https://www.nature.com/articles/s41591-021-01270-4)
153 4
- 154 3. Garcia-Beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, et al.
155 Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral
156 immunity. *medRxiv* [Internet]. 2021 Mar 2.
157 <https://www.medrxiv.org/content/10.1101/2021.02.14.21251704v1>
- 158 4. Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular
159 dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the
160 combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces
161 conformational change greater than N501Y mutant alone, potentially resulting in an
162 escape mutant. *bioRxiv* [Internet]. 2021 Mar 3.
163 <https://www.biorxiv.org/content/10.1101/2021.01.13.426558v1>
- 164 5. Liu H, Wei P, Zhang Q, Chen Z, Aviszus K, Downing W, et al. 501Y.V2 and 501Y.V3
165 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. *bioRxiv* [Internet]. 2021
166 Mar 2. <https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1>
- 167 6. Public Health England. Investigation of novel SARS-COV-2 variant: Variant of Concern
168 202012 / 01. 2020 Dec 21 [cited 2021 Mar 3].

- 169 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_d](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf)
170 [ata/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf)
- 171 7. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A.
172 Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January
173 12, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(3):95–9.
- 174 8. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2
175 variant with multiple spike protein mutations observed in the United Kingdom. 2020 Dec
176 20 [cited 2021 Mar 3]. [https://www.ecdc.europa.eu/sites/default/files/documents/SARS-](https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf)
177 [CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf)
- 178 9. Souza WM, Amorim MR, Sesti-Costa R, Coimbra LD, Toledo-Teixeira DA, Parise PL, et
179 al. Levels of SARS-CoV-2 lineage P.1 neutralization by antibodies elicited after natural
180 infection and vaccination. *Pre-Prints with Lancet [Internet]*. 2021 Mar 2.
181 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3793486
- 182 10. MiCall: Processing FASTQ data from an Illumina MiSeq. [cited 2021 Mar 3].
183 <https://github.com/cfe-lab/MiCall>
- 184 11. VirSNiP SARS-CoV-2 Spike K417N Package Insert, TIB Molbiol, Germany. 2020;
- 185 12. World Health Organization. Genomic sequencing of SARS-CoV-2: A guide to
186 implementation for maximum impact on public health. 2021 Jan 8 [cited 2021 Mar 3].
187 <https://www.who.int/publications/i/item/9789240018440>
- 188 13. Ontario Agency for Health Protection and Promotion (Public Health Ontario), Provincial
189 Infectious Diseases Advisory Committee. Interim guidance for infection prevention and
190 control of SARS-CoV-2 variants of concern for health care settings. 2021 Feb 10 [cited
191 2021 Mar 3]. [https://www.publichealthontario.ca/-](https://www.publichealthontario.ca/)

- 192 /media/documents/ncov/voc/2021/02/pidac-interim-guidance-sars-cov-2-
193 variants.pdf?la=en
- 194 14. European Centre for Disease Prevention and Control. Risk Assessment: Risk related to the
195 spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. 2021 Jan 21
196 [cited 2021 Mar 3]. [https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-
197 assessment-spread-new-variants-concern-eueea-first-update](https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update)
- 198 15. Zhang W, Davis B, Chen S, Sincuir Martinez JM, Plummer JT, Vail E. Emergence of a
199 Novel SARS-CoV-2 Variant in Southern California. JAMA [Internet]. 2021 Feb 28.
200 <https://jamanetwork.com/journals/jama/fullarticle/2776543>
201
202

203 **Figure:** Detection rate of SARS-CoV-2 variants of concern by day of result for the study period
204 of January 25 to March 1, 2021, with 7-day moving average

B.1.1.7 (UK)**B.1.351 (South African)****B.1.1.28/P.1 (Brazilian)**